This content is from: European Union

AstraZeneca faces Losec investigation

The world's biggest selling drug is under attack on both sides of the Atlantic as its patent expiry looms. AstraZeneca, maker of Losec, has been accused of breaching European competition rules, and is also facing litigation to stop US companies bringing out generic versions of the drug.

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | One Week Trial